Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (331-340 of 406) with videos related to

Pageof 41
Sort By:
Dermatology and Therapy|September 12, 2021
Practical Management of Patients with Atopic Dermatitis on DupilumabKim A Papp, Chih-Ho Hong, M Perla Lansang, et al.
American Journal of Clinical Dermatology|November 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesEric L Simpson, Matthias Augustin, Diamant Thaçi, et al.
The Journal of Rheumatology|February 3, 2019
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 23, 2018
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive TherapiesKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|October 17, 2019
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
American Journal of Clinical Dermatology|July 29, 2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Dermatology and Therapy|December 10, 2022
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month DataKim A Papp, Melinda Gooderham, Ignacio Dei-Cas, et al.
Pageof 41

Showing results (331-340 of 406) with videos related to

Sort By:
Pageof 41
Dermatology and Therapy|September 12, 2021
Practical Management of Patients with Atopic Dermatitis on DupilumabKim A Papp, Chih-Ho Hong, M Perla Lansang, et al.
American Journal of Clinical Dermatology|November 15, 2024
Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III StudiesEric L Simpson, Matthias Augustin, Diamant Thaçi, et al.
The Journal of Rheumatology|February 3, 2019
Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 3, 2021
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyondJ Beecker, K A Papp, J Dutz, et al.
Journal of Cutaneous Medicine and Surgery|November 23, 2018
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive TherapiesKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
Journal of the Canadian Association of Gastroenterology|October 17, 2019
Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive SummaryKim A Papp, Boulos Haraoui, Deepali Kumar, et al.
American Journal of Clinical Dermatology|July 29, 2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial ResultsKim A Papp, Mark G Lebwohl, Lluís Puig, et al.
Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.
Dermatology and Therapy|December 10, 2022
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month DataKim A Papp, Melinda Gooderham, Ignacio Dei-Cas, et al.
Pageof 41